J-TEC develops autologous cell products under AMED contract

J-TEC, now a Fujifilm company, has started two projects under the Japan AMED mechanism (an NIH-type funding): the development of autologous epidermis including physician-led clinical trials for skin reconstruction, and the expansion of autologous mesenchymal stem cells for applications in ischemic diseases.

April 12, 2016

J-TEC develops autologous cell products under AMED contract
Scroll to top